The present invention is related to novel methods for identifying a population of subjects that are at risk for developing of atopic allergic diseases, such as atopic dermatitis, and to the prevention and treatment of these allergic diseases.

Provided are a marker for detecting atopic dermatitis, and a method for detecting atopic dermatitis using the marker. The method for detecting atopic dermatitis in a test subject comprises a step of measuring an expression level of a gene or an expression product thereof contained in a biological sample collected from the test subject.

The present invention provides compounds and methods targeting human interleukin-19, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications useful in the field of immune-mediated diseases including psoriasis, atopic dermatitis, psoriatic arthritis, bronchial asthma and diabetic nephropathy.

The present invention features biomarkers for diagnosis and treatment of dermatological diseases, e.g., psoriasis and atopic dermatitis. The disclosure provides a minimally invasive method of determining levels of biomarkers (e.g., NOS2/iNOS) in surface skin samples.

The present invention provides compounds and methods targeting human interleukin-19, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications useful in the field of immune-mediated diseases including psoriasis, atopic dermatitis, psoriatic arthritis, bronchial asthma and diabetic nephropathy.

The present invention provides methods for treating atopic dermatitis (AD). Also provided are methods for improving one or more AD-associated parameter(s), and methods for decreasing the level of at least one AD-associated biomarker in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.

Methods and compositions are provided herein for treating atopic dermatitis in a subject, using one or more bacterial strains such as Brevundimonas nasdae W1-2B, Capnocytophaga sputigena 4, Moraxella sp. LMG 5131, Neisseria elongata ATCC 29315, Staphylococcus felis GD521, Staphylococcus sciuri SC116, or Streptococcus intermedius 393.

The invention relates to biomarkers in children's skin, in particular in the skin of infants, the expression of which changes when the skin is affected by atopic dermatitis. Such markers are particularly advantageous in that they allow the skin's response to atopic dermatitis to be monitored. The inventors have developed methods for evaluating the in vitro efficacy of formulations in preventing the effects of atopic dermatitis on a child's skin, using a skin model specifically capable of reproducing the characteristics of children's skin.

Provided are methods of diagnosis and treatment of atopic dermatitis.

An object of the present disclosure is to provide a novel method for detecting atopic dermatitis and a novel method for determining a therapeutic effect on atopic dermatitis. The present disclosure provides a method for detecting atopic dermatitis, including the step of measuring the concentration of a lipid metabolite in a biological sample of a subject. The present disclosure also provides a method for determining a therapeutic effect on atopic dermatitis, including the step of measuring the concentration of a lipid metabolite in a biological sample of a subject.